JP2005513049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513049A5 JP2005513049A5 JP2003550787A JP2003550787A JP2005513049A5 JP 2005513049 A5 JP2005513049 A5 JP 2005513049A5 JP 2003550787 A JP2003550787 A JP 2003550787A JP 2003550787 A JP2003550787 A JP 2003550787A JP 2005513049 A5 JP2005513049 A5 JP 2005513049A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen atom
- halogen
- formula
- independent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 37
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010065433 Ligament rupture Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010057178 Osteoarthropathies Diseases 0.000 claims 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000005499 meniscus Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 210000004417 patella Anatomy 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005801 spondylosis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10160357A DE10160357A1 (de) | 2001-12-08 | 2001-12-08 | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
| PCT/EP2002/013240 WO2003049738A1 (de) | 2001-12-08 | 2002-11-25 | Verwendung von pyridin-2,4-dicarbonsäurediamiden und pyrimidin-4,6-dicarbonsäurediamiden zur selektiven inhibierung von kollagenasen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513049A JP2005513049A (ja) | 2005-05-12 |
| JP2005513049A5 true JP2005513049A5 (https=) | 2006-01-12 |
| JP4527980B2 JP4527980B2 (ja) | 2010-08-18 |
Family
ID=7708512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550787A Expired - Fee Related JP4527980B2 (ja) | 2001-12-08 | 2002-11-25 | 選択的コラゲナーゼ阻害のためのピリジン−２，４−ジカルボン酸ジアミドおよびピリミジン−４，６−ジカルボン酸ジアミドの使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1455790B1 (https=) |
| JP (1) | JP4527980B2 (https=) |
| AT (1) | ATE390137T1 (https=) |
| AU (1) | AU2002358535B2 (https=) |
| CA (1) | CA2469625C (https=) |
| DE (2) | DE10160357A1 (https=) |
| IL (2) | IL162314A0 (https=) |
| MX (1) | MXPA04005129A (https=) |
| WO (1) | WO2003049738A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| WO2002064571A1 (en) | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyrimidine matrix metalloproteinase inhibitors |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| BR0213233A (pt) | 2001-10-12 | 2005-01-04 | Warner Lambert Co | Alcinos inibidores de metaloproteinase de matriz |
| KR101050680B1 (ko) * | 2002-11-02 | 2011-07-21 | 사노피-아벤티스 도이칠란트 게엠베하 | 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드 |
| DE10300017A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Selektive MMP 13 Inhibitoren |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CA2608890C (en) * | 2005-05-20 | 2011-08-02 | Alantos-Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| CA2658362A1 (en) * | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| WO2009140101A2 (en) * | 2008-05-12 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Imidazopyridine compounds useful as mmp-13 inhibitors |
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931432A1 (de) * | 1989-09-21 | 1991-04-04 | Hoechst Ag | Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
| DE4020570A1 (de) * | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung |
| DOP2002000332A (es) * | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| DOP2002000333A (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| WO2002064571A1 (en) * | 2001-02-14 | 2002-08-22 | Warner-Lambert Company Llc | Pyrimidine matrix metalloproteinase inhibitors |
-
2001
- 2001-12-08 DE DE10160357A patent/DE10160357A1/de not_active Withdrawn
-
2002
- 2002-11-25 MX MXPA04005129A patent/MXPA04005129A/es active IP Right Grant
- 2002-11-25 EP EP02792799A patent/EP1455790B1/de not_active Expired - Lifetime
- 2002-11-25 CA CA2469625A patent/CA2469625C/en not_active Expired - Fee Related
- 2002-11-25 AU AU2002358535A patent/AU2002358535B2/en not_active Ceased
- 2002-11-25 IL IL16231402A patent/IL162314A0/xx unknown
- 2002-11-25 JP JP2003550787A patent/JP4527980B2/ja not_active Expired - Fee Related
- 2002-11-25 DE DE50211985T patent/DE50211985D1/de not_active Expired - Lifetime
- 2002-11-25 AT AT02792799T patent/ATE390137T1/de not_active IP Right Cessation
- 2002-11-25 WO PCT/EP2002/013240 patent/WO2003049738A1/de not_active Ceased
-
2004
- 2004-06-02 IL IL162314A patent/IL162314A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2219167C2 (ru) | N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств | |
| CN1032750C (zh) | 新的聚4-氨基-2-羟基-1-甲基化合物脲基衍生物的制备方法 | |
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| JP2005513049A5 (https=) | ||
| RU2220143C2 (ru) | Оптически активные производные бензопирана, фармацевтическая композиция на их основе и способ лечения чувствительных к эстрогенам заболеваний | |
| RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
| RU95102778A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен | |
| JP3838657B2 (ja) | 薬学的組成物 | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| TNSN04164A1 (fr) | Inhibiteurs de acc. | |
| HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| JPH06510041A (ja) | 抗ｈｉｖ（ａｉｄｓ）薬剤 | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| RU94043811A (ru) | Применение 2-фенил-3-ароилбензтиофенов для лечения менструальных симптомов, фармацевтические композиции | |
| WO2001039759A3 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
| BR9612423A (pt) | Composto, composição farmacêutica, e, processo para tratar um estado doentio. | |
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| KR960022542A (ko) | 광학 활성 벤조티에핀 유도체, 그의 제조방법 및 용도 | |
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| CA2274686A1 (en) | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
| RU2004107261A (ru) | Арилсульфонильные производные, обладающие сродством к рецептору 5-нт6 | |
| NO20005912L (no) | Sulfonylsyre- eller sulfonylamino-N-(heteroaralkyl)- azaheterocyklylamidforbindelser |